Introduction {#sec1}
============

Transition metal-catalyzed C--H bond functionalization has evolved rapidly because of its potential to create a diverse range of products efficiently without the requirement to prepare preactivated starting material.^[@ref1]^ The advantages of this methodology are that it is atom economical, has a reduced number of reaction steps, and produces minimal waste.^[@ref2]^ Transition metal catalysts are effective and efficient for annulation via chelation-assisted functionalization of C--H/N--H and/or C--H/O--H bonds.^[@ref3]^ Even though great advances in C--H annulation have been executed in recent years, the skill to selectively functionalize precise sp^2^ C--H bonds in the presence of contending C--H bonds persists as the critical and strategic feature for the success of this tandem process.^[@ref4]^

Cancer is the primary cause of death in developed countries and the second leading cause of death in developing countries.^[@ref5]^ Improvement in the methodology for early detection of benign and propagated tumor cells in patients is extremely significant to the success of cancer therapy and improvement in the survival rates of patients.^[@ref6]^ Nowadays, optical imaging methodologies are evolving as promising noninvasive, real-time and high-resolution modalities for the diagnosis of cancer.^[@ref7]^ Because of better cell permeability and minimal perturbation to living systems, low molecular weight organic fluorophores are extremely appropriate for biological studies.^[@ref8]^ Among the organic fluorophores for in vivo bioanalysis and bioimaging, far red/near-infrared (FR/NIR) fluorophores (λ = 650--900 nm)^[@ref9]^ have been shown to be promising molecules due to their low-light scattering, deep-tissue penetration and marginal photodamage.^[@ref10]^ Hence, the FR/NIR fluorescent probes are likely to be appropriate for biological imaging.^[@ref11]^ However, the development of novel FR/NIR fluorophores with requisite properties for biological imaging is an appealing and significantly challenging task.

For proficient cancer cell fluorescence imaging, FR/NIR probes must exhibit greater chemical and photophysical properties, such as high quantum yield for intense fluorescence, large Stokes shift for least interference between absorption and emission spectra, adequate chemical and photostability in solvents, buffers, or biological conditions, less cytotoxicity, and suitable chemical functionality for bioconjugation with specific scaffolds for the purpose of targeting. For the construction of fluorescent probes, polycyclic heteroaromatic molecules (PHAs) with extended π-conjugated structures have been proven to be better chromophores in numerous reports. Significantly, PHAs are disclosed as NIR-active dyes, two-photon absorbers, and fluorescence sensors.^[@ref12]^

We have already explored Rh(III)-catalyzed dehydrogenative C--H/N--H functionalization to synthesize cinnoline derivatives as fluorescent probes for live cancer cell imaging in our recent work.^[@ref13]^ In the course of our efforts on the development of novel transition metal-catalyzed C--H functionalization^[@ref14]^ and annulation reactions,^[@ref15]^ with the aim of design and synthesis of novel organic fluorophores,^[@ref16]^ we report here Ru(II)-catalyzed regiospecific C--H/O--H oxidative annulation reaction to synthesize isochromeno\[8,1-*ab*\]phenazine, which was successfully applied as an FR fluorescent probe for live cancer cell imaging.

Results and Discussion {#sec2}
======================

Synthesis of Isochromeno\[8,1-*ab*\]phenazines {#sec2.1}
----------------------------------------------

Initially, benzo\[*a*\]phenazin-5-ol **1a** was treated with \[RuCl~2~(*p*-cymene)\]~2~ (5 mol %), AgSbF~6~ (20 mol %), Cu(OAc)~2~·H~2~O (1 equiv), and diphenyl acetylene **2a** (1.5 equiv) in toluene (5 mL) at 110 °C under nitrogen for 12 h. After completion of the reaction evidenced by thin-layer chromatography (TLC), the product **3a** was isolated by column chromatography, with the yield of 14% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). The structure of the product was confirmed as a highly substituted isochromeno\[8,1-*ab*\]phenazine (**3a**) using various analytical techniques, such as high-resolution mass spectrometry (HRMS), ^1^H and ^13^C NMR, and single crystal X-ray diffraction ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00335/suppl_file/ao7b00335_si_001.pdf)). When the reaction was performed under air, the yield was improved to 30% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 2). Switching the solvent from toluene to chlorobenzene (PhCl) under identical reaction conditions provided the annulated product **3a** in an improved yield of 40%. When other solvents, such as 1,4-dioxane, *t-*AmOH, CH~3~OH, dimethylformamide (DMF), and 1,2-dichloroethane (1,2-DCE) ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 3--7) were employed in this reaction, 1,2-DCE provided the best yield of 72% ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 7). Further, varying the oxidant from Cu(OAc)~2~·H~2~O to Cu(OAc)~2~, AgOAc, Ag~2~CO~3~, K~2~S~2~O~8~, and PhI(OAc)~2~ under identical conditions to that of [Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 7, did not improve the yield of product **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 8--12). Reducing the amount of oxidant to 0.5 equiv decreased the yield, and without the oxidant, it failed to afford the desired compound **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 13--14). Similarly, replacing AgSbF~6~ with other additives, such as KPF~6~ and AgBF~4~, afforded the product in reduced yields ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 15--16). Absence of the additive AgSbF~6~ also delivered very low yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 17). Moreover, replacing the catalyst \[RuCl~2~(*p*-cymene)\]~2~ with RuCl~2~·5H~2~O, \[RhCp\*Cl~2~\]~2~ and Pd(OAc)~2~ did not improve the results ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 18--20).

###### Optimization of the Reaction Condition of Benzo\[*a*\]phenazin-5-ol with Diphenyl Acetylene[a](#t1fn1){ref-type="table-fn"}

![](ao-2017-003356_0005){#fx1}

  entry                                catalyst                     oxidant            solvent       yield (%)[b](#t1fn2){ref-type="table-fn"}
  ------------------------------------ ---------------------------- ------------------ ------------- -------------------------------------------
  1                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   toluene       14[c](#t1fn3){ref-type="table-fn"}, 30
  2                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   Cl-benzene    40
  3                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   1,4-dioxane   10
  4                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   *t-*AmOH      20
  5                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   CH~3~OH       18
  6                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   DMF           30
  7                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   1,2-DCE       72
  8                                    \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~         1,2-DCE       68
  9                                    \[RuCl~2~(*p*-cymene)\]~2~   AgOAc              1,2-DCE       45
  10                                   \[RuCl~2~(*p*-cymene)\]~2~   Ag~2~CO~3~         1,2-DCE       25
  11                                   \[RuCl~2~(*p*-cymene)\]~2~   K~2~S~2~O~8~       1,2-DCE       18
  12                                   \[RuCl~2~(*p*-cymene)\]~2~   PhI(OAc)~2~        1,2-DCE       trace
  13[d](#t1fn4){ref-type="table-fn"}   \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   1,2-DCE       28
  14                                   \[RuCl~2~(*p*-cymene)\]~2~   −                  1,2-DCE       0
  15[e](#t1fn5){ref-type="table-fn"}   \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   1,2-DCE       65
  16[f](#t1fn6){ref-type="table-fn"}   \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   1,2-DCE       50
  17[g](#t1fn7){ref-type="table-fn"}   \[RuCl~2~(*p*-cymene)\]~2~   Cu(OAc)~2~·H~2~O   1,2-DCE       10
  18                                   RuCl~2~·5H~2~O               Cu(OAc)~2~·H~2~O   1,2-DCE       trace
  19                                   \[RhCp\*Cl~2~\]~2~           Cu(OAc)~2~·H~2~O   1,2-DCE       60
  20[g](#t1fn7){ref-type="table-fn"}   Pd(OAc)~2~                   Cu(OAc)~2~         DMF           trace

Reaction conditions: **1a** (0.3 mmol), **2a** (0.3 mmol), catalyst (5.0 mol %), additive AgSbF~6~ (20 mol %), and oxidant (1 equiv) in the indicated solvent (2.0 mL) at reflux or 110 °C for 12 h under air.

Isolated yield.

Under nitrogen.

Oxidant (0.5 equiv).

KPF~6~ was employed instead of AgSbF~6~.

AgBF~4~ was employed instead of AgSbF~6~.

Without additive.

Under optimized reaction conditions, we first scrutinized the scope of versatility in the oxidative annulation of benzo\[*a*\]phenazin-5-ol **1a** by employing diversely substituted alkynes (**2a**--**m**) ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}). Symmetric diaryl acetylenes bearing various substitutions such as electron-donating methyl and methoxy at the para position coupled smoothly with **1a** in 65 and 57% yields, respectively (**3b**--**c**). Diaryl acetylene bearing halogen groups at the para position of the benzene ring was generally well tolerated and afforded products **3d**--**f** in moderate to good isolated yields of 50--64%. Substitution of the strong electron-withdrawing groups at the para position of the phenyl ring provided **3g** in 39% yield. This reaction is also compatible with 1,2-di(naphthalene-diaryl acetylene) by which product **3h** was isolated in 50% of the yield.

###### Ru(II)-Catalyzed Regiospecific C--H/O--H Oxidative Annulation of Benzo\[*a*\]phenazin-5-ol with Alkynes[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

![](ao-2017-003356_0009){#fx2}

Reaction conditions: **1** (0.3 mmol), **2** (0.3 mmol), \[RuCl~2~(*p*-cymene)\]~2~ (5.0 mol %), Cu(OAc)~2~·H~2~O (1 equiv), and AgSbF~6~ (20 mol %) in 1,2-DCE at reflux for 12 h under air.

Isolated yield.

To understand the regioselectivity of the present reaction, unsymmetrical alkyne was used as the substrate for the reaction with **1a**. Thus, 1-phenyl-1-propyne acetylene **2i** gave the single regioisomeric product **3i** in 68% yield. The present catalytic reaction was successfully extended to the symmetrical aliphatic alkynes **2j**--**m**, which offered moderate to good isolated yields (**3j**--**m**). We next explored the scope and limitations of benzo\[*a*\]phenazin-5-ol substrates (**1b--h**) in this coupling reaction with diphenyl acetylene **2a**. Dibromo substitutions in benzo\[*a*\]phenazin-5-ol decreased yield of the product **3o** (58%). Diphenyl substitutions in the ortho and para positions afforded **3p** and **3q** in 67 and 70% yield, respectively. The reaction underwent smoothly with highly substituted triphenylamine tagged benzo\[*a*\]phenazin-5-ol and yielded **3r** in 56%. In addition, substitution of the electron-withdrawing groups, such as CN, delivered the product **3s** in 67% yield. Interestingly, a very high yield of **3t** (80%) was observed when the phenyl ring was replaced by the cyclohexyl ring.

To check intermolecular competitive reaction between the electron-deficient diphenyl acetylene (**2a**) and electron-rich 4-octyne (**2l**), we studied the annulation reaction, as indicated in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. Benzo\[*a*\]phenazin-5-ol (**1a**) was reacted with an equimolar mixture of **2a** and **2l** under optimized conditions. Notably, the annulated product, **3a**, originating from the electron-deficient alkyne (**2a**), was obtained in higher proportion (1.7/1.0) compared to that of product **3l**, originating from the electron-rich alkyne (**2l**).

![Control Experiment](ao-2017-003356_0006){#sch1}

To achieve a preliminary understanding of the mechanism, deuterium exchange experiments were conducted. Heating the combination of **1a** and CD~3~OD in 1,2-DCE at 100 °C provided **1aa**, with one incorporated D atom ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}, eq 1). Under the standard procedure, heating the combination of **1a** and CD~3~OD in 1,2-DCE at 100 °C provided **1ab** in a significant D/H exchange in the peri-position ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}, eq 2), thereby providing evidence for the reversible C--H bond ruthenation step in this annulation reaction. In both reactions, no O--H deuteration was detected, which could be rationalized by the labile O--D/H exchange during the workup on silica gel chromatography.

![Preliminary Mechanism Study](ao-2017-003356_0010){#sch2}

On the basis of the experimental results and previous report,^[@ref17]^ the plausible mechanism for the formation of isochromeno\[8,1-*ab*\]phenazine (**3**) by the direct Ru(II)-catalyzed cyclisation of benzo\[*a*\]phenazin-5-ol (**1**) with alkynes (**2**) is shown in [Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}. The additive AgSbF~6~ likely initiates the catalytic reaction by dissociation of the dimeric form of the ruthenium complex \[RuCl~2~(*p*-cymene)\]~2~ and gives a reactive cationic ruthenium species. Then, the ruthenium complex gets attached with the directing group OH and forms the intermediate **A**. Then, peri*-*C--H metalation of the intermediate **A** provides a five-membered ruthenacycle intermediate **B**. Now, alkyne **2** attaches with the intermediate **B** giving rise to intermediate **C**. At this point, coordinative regioselective insertion of alkyne **2** into the Ru--C bond of intermediate **C** gives intermediate **D**. Finally, the ruthenium complex that is regenerated by Cu(OAc)~2~ forms the isochromeno\[8,1-*ab*\]phenazine (**3**).

![Plausible Mechanism for the Ru(II)-Catalyzed Regiospecific C--H/O--H Oxidative Annulation of Benzo\[*a*\]phenazin-5-ol with Alkynes](ao-2017-003356_0011){#sch3}

Photophysical Properties {#sec2.2}
------------------------

After we had a diverse library of isochromeno\[8,1-*ab*\]phenazine in hand, their photophysical properties in solution and thin-film states, including absorptions, emissions, and quantum yields, were investigated ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00335/suppl_file/ao7b00335_si_001.pdf)).^[@ref18]^ It is worth mentioning that synthesized compounds exhibit emissions (λ~max,em~: 532--632 nm in dichloromethane (DCM); 565--640 nm in thin-film) with large Stokes shifts (up to 4853 cm^--1^ in DCM; 5747 cm^--1^ in thin-film) and high fluorescence quantum yields (up to 86% in DCM) ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}).

###### Optical Properties of Compounds (**3a**--**v**)

           λ~max,ab~ (nm)   λ~max,em~ (nm)   Stokes shift[e](#t3fn5){ref-type="table-fn"} (cm^--1^)   quantum yield                 
  -------- ---------------- ---------------- -------------------------------------------------------- --------------- ------ ------ ------
  **3a**   494              508              553                                                      590             2160   2736   0.54
  **3b**   498              511              559                                                      585             2191   2475   0.43
  **3c**   500              514              572                                                      604             2517   2899   0.48
  **3d**   490              504              544                                                      619             2026   3686   0.35
  **3e**   489              496              540                                                      565             1931   2462   0.37
  **3f**   488              501              539                                                      565             1939   2261   0.39
  **3h**   486              498              538                                                      566             1989   2412   0.32
  **3i**   495              497              554                                                      566             2151   2453   0.45
  **3j**   497              550              563                                                      599             2359   1487   0.41
  **3k**   501              527              563                                                      579             2198   1704   0.47
  **3l**   499              503              563                                                      581             2278   2669   0.52
  **3m**   503              510              567                                                      588             2244   2601   0.65
  **3n**   491              503              544                                                      573             1984   2429   0.37
  **3o**   518              529              580                                                      616             2064   2670   0.12
  **3p**   507              521              559                                                      607             1835   2719   0.86
  **3q**   503              509              551                                                      582             1732   2464   0.23
  **3r**   516              525              568                                                      599             1774   2353   0.37
  **3s**   501              512              594                                                      630             3125   3658   0.17
  **3t**   431              435              545                                                      580             4853   5747   0.52
  **3u**   526              532              609                                                      640             2591   3172   0.28
  **3v**   511              540              632                                                      637             3747   2820   0.22

Sol---in DCM solvent at 5 μM.

TF---thin-film.

Excitation wavelength: 450--500 nm.

Excitation wavelength: 450--540 nm.

Stokes shift = λ~max,ab~ -- λ~max,em~ (cm^--1^).

Determined by fluorescein (Φ~F~ = 0.79), as a standard in 0.1 M ethanol solution.

Compound **3a** displays emissions (λ~max,em~) of 553 and 590 nm with Stokes shifts of 2160 and 2736 cm^--1^ in DCM and thin film, respectively, and fluorescence quantum yield of 54% in DCM. We studied the impact of R~1~ and R~2~ in the aromatic alkynes by varying the substitution by **3b** (R~1~ = R~2~ = CH~3~), **3c** (R~1~ = R~2~ = OCH~3~), **3d** (R~1~ = R~2~ = F), **3e** (R~1~ = R~2~ = Cl), **3f** (R~1~ = R~2~ = Br), and **3g** (R~1~ = R~2~ = NO~2~). Interestingly, OCH~3~ (**3c**) and F (**3d**) substitutions increase the emission value, with larger Stokes shifts when compared to the results with compound **3a**. However, compound **3c** shows quantum yield of 48%, which is comparable to **3a** (54%), whereas **3d** shows lesser quantum yield of 35%. On the other hand, NO~2~ substitution quenched the fluorescence.

When a naphthyl ring (**3h**) was employed instead of a phenyl ring (**3a**), compound **3h** showed a reduced emission wavelength and quantum yield. Subsequently, the influence of the R~1~ and R~2~ substituents in the aliphatic alkynes (**3j**--**m**) was examined. Compounds **3j** (R~1~ = R~2~ = CH~3~), **3k** (R~1~ = R~2~ = CH~2~CH~3~), **3l** (R~1~ = R~2~ = (CH~2~)~2~CH~3~), and **3m** (R~1~ = R~2~ = (CH~2~)~3~CH~3~) demonstrate similar absorptions (497, 501, 499, and 503 nm, respectively) and emission wavelengths (563, 563, 563, and 567 nm, respectively) in DCM. However, compound **3m** exhibits higher quantum yield of 65% compared to that with **3j** (41%).

Once variations in the alkynes were studied, we then explored the variations in benzo\[*a*\]phenazin-5-ol (**1**). When comparing the emission wavelengths of compounds **3a** and **3n**--**r**, a notable bathochromic shift was observed for the compounds **3o**, **3p**, and **3r**. Even though **3o** and **3r** show lesser quantum yield of 12 and 37%, respectively, compound **3p**, shows a much higher quantum yield of 86% compared to that of **3a** (54%). When the phenyl ring in **3a** was replaced by the cyano groups (**3s**), a significant bathochromic shift was observed from 590 to 630 nm, with a large Stokes shift change from 2736 to 3658 cm^--1^. The phenyl ring in **3a** was replaced by the cyclohexyl ring (**3t**), whereas a much higher rise in Stokes shift from 2736 to 5747 cm^--1^ was observed, with only a slight variation of the emission wavelengths and quantum yield.

After we examined the physical properties of the diverse substituted compounds, we designed **3u** and **3v** by the combination of **3c**, **3o**, and **3s** to obtain compounds with enhanced physical properties. Compounds **3u** and **3v** disclose a large bathochromic shift with wavelengths of 637 and 640 nm, respectively ([Figures [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"} and [2](#fig2){ref-type="fig"}).

![Designed compounds to enhance the fluorescence in FR region.](ao-2017-003356_0007){#fig1}

![(A) Normalized absorption (dash line) and fluorescence (solid line) spectra of **3p** in DCM (blue) and thin-film (red). (B) Normalized absorption (dash line) and fluorescence (solid line) spectra of **3u** in DCM (blue) and thin-film (red).](ao-2017-003356_0008){#fig2}

The fluorescence solvatochromism of **3p** was studied in several solvents, and the results are presented in [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}. Compound **3p** displays a large positive solvatochromism, with strong fluorescence. Compound **3p** unveils solvatochromism with a bathochromic shift by an increase in the solvent polarity from toluene to dimethyl sulfoxide, the green, yellow, orange, and red regions of the visible spectrum covering them. Notably, the fluorescence of compound **3p** in methanol shifted radically to the higher wavelength (λ~max,em~ = 610 nm). The reason for this strong solvatochromism is owing to the combination of intramolecular charge transfer and dipole--solvent interactions in solution.^[@ref19]^

![Emission spectra of **3p** in various solvents. Inset in panel: photo of **3p** in various solvents taken under UV luminescence.](ao-2017-003356_0012){#fig3}

Density Functional Theory (DFT) Calculations {#sec2.3}
--------------------------------------------

DFT calculation of compound **3p** at B3LYP-6-311G level was estimated, and the results are shown in [Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}. On the basis of the DFT calculation, the lowest unoccupied molecular orbital (LUMO) is mostly covered on the phenazine moiety, whereas the highest occupied molecular orbital (HOMO) is largely confined around the chromene moiety.

![Pictorial presentation of the HOMO (A) and LUMO (B) diagrams of **3p**.](ao-2017-003356_0001){#fig4}

Application for Live Cancer Cell Imaging {#sec2.4}
----------------------------------------

For live cancer cell imaging, **3p** was investigated using various cancer cells, such as A549 (lung cancer cells), HepG2 (liver cancer cells), and U937 (lymphoma cells), due to its high quantum yield.^[@ref20]^ Compound **3p** (10 μM) was added to the tested cell cultures and incubated at 37 °C for 30 min. Later, the cells were stained with nucleus staining dye 4′,6-diamidino-2-phenylindole (DAPI) (2 μM) for another 20 min. To our delight, **3p** effectively entered the cell membranes of the tested cancer cells, labeled with an intense FR luminescence when compared to the fluorescence images of the cells before and after the treatment with **3p** ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}). This showed the potential of compound **3p** in intracellular imaging in the tested cancer cells. It is noteworthy that during the cell imaging experiment, the tested cells were healthy and unharmed and displayed an adherent morphology. From this study, we conclude that compound **3p** could be used for live cancer cell imaging ([Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00335/suppl_file/ao7b00335_si_001.pdf)).

![Live cell imaging of compound **3p** in A549, HepG2, and U937 cells. (A) Row 1 (a1--a3): A549 cells treated with 10 μM **3p** for 30 min. (B) Row 2 (b1--b3): HepG2 cells treated with 10 μM **3p** for 30 min. (C) Row 3 (c1--c3): U937 cells treated with 10 μM **3p** for 30 min. For (A)--(C), column 1 (a1--c1): DAPI-stained blue fluorescence images; column 2 (a2--c2): red fluorescence images; column 3 (a3--c3): merging of the blue and red fluorescence images. Scale bar = 10 μm. Excitation and emission wavelength: 405 and 410--460 nm for blue fluorescence images; 561 and 570--680 nm for red fluorescence images.](ao-2017-003356_0002){#fig5}

Cell Viability Assay {#sec2.5}
--------------------

We studied the cytotoxicity of the synthesized compound **3p**, which is an important factor for cell-imaging applications ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}). The MTS assay method was applied to test the cytotoxicity of compound **3p** by adding up to 200 μM of the compound in the tested cancer cell culture. The observed cytotoxicity is very nominal for compound **3p** against that of the tested cancer cells, such as A549, HepG2, and U937. Because of the excellent biocompatibility, the synthesized compound **3p** could be utilized as a fluorescent bioprobe in live cancer cell imaging.

![Cell viability assay in A549, HepG2, and U937 cells using MTS reagent. Cells have been incubated with **3p** (0--200 μM) for 48 h.](ao-2017-003356_0003){#fig6}

Conclusions {#sec3}
===========

In summary, we developed a novel Ru(II)-catalyzed C--H/O--H oxidative annulation reaction to obtain isochromeno\[8,1-*ab*\]phenazines. This synthetic methodology offers various advantages, such as diverse substrates in a range of functional groups executed under air, and yields regioselective products. This methodology was successfully applied to design and synthesize FR fluorescent probes for live cancer cell imaging. Photophysical properties were examined both in solution and thin-film states. Notably, synthesized compounds displayed green to FR emissions with large Stokes shifts and high fluorescence quantum yields. Furthermore, **3p** shows a large positive solvatochromism, with strong fluorescence. To study the photophysical properties, DFT calculation was done to look at the possible HOMO and LUMO properties. Among the synthesized compounds, **3p** was investigated for live cancer cell imaging due to its high quantum yield. Compound **3p** labeled the cancer cells efficiently with an intense FR luminescence by passing through the cell membranes. It is noteworthy that the tested cells were unharmed and displayed an adherent morphology during the cell-imaging experiments. We successfully demonstrated **3p** as a fluorescent bioprobe in live cancer cell imaging, as a result of its prominent FR fluorescence, high quantum yield, and excellent biocompatibility.

Experimental Section {#sec4}
====================

Materials and Methods {#sec4.1}
---------------------

Reagents and solvents were purchased from commercial sources. \[RuCl~2~(*p*-cymene)\]~2~, Cu(OAc)~2~·H~2~O, and AgSbF~6~ were used as purchased, without further purification, unless otherwise noted. Column chromatography was performed on silica gel (100--200 mesh). Analytical TLC was performed on precoated aluminum sheets of silica gel 60F254 of 0.2 mm thickness. Melting points were determined in capillary tubes and remain uncorrected. ^1^H NMR (400 MHz) and ^13^C NMR (100 MHz) spectra were recorded in CDCl~3~ solution, with tetramethylsilane as internal standard. HRMS electrospray ionization (ESI) were recorded using HRMS. UV--visible absorption spectra were recorded using UV spectrophotometer. The steady state fluorescence measurements were recorded using fluorescence spectrophotometer. Cell imaging was done using laser confocal microscope instrument.

Synthetic Procedures {#sec4.2}
--------------------

### General Procedure for Synthesis of Isochromeno\[8,1-*ab*\]phenazines (**3a**--**v**) {#sec4.2.1}

To an oven-dried 25 mL round-bottom flask fitted with a reflux condenser were added benzo\[*a*\]phenazin-5-ol **1a** (73.88 mg, 0.3 mmol, 1.0 equiv), diphenyl acetylene **2a** (53.43 mg, 0.3 mmol, 1.0 equiv), \[RuCl~2~(*p*-cymene)\]~2~ (9.18 mg, 0.015 mmol, 0.05 equiv), AgSbF~6~ (20.62 mg, 0.06 mmol, 0.2 equiv), Cu(OAc)~2~·H~2~O (59.89 mg, 0.3 mmol, 1.0 equiv) in 3.0 mL of 1,2-DCE. The reaction mixture was refluxed for 12 h. After cooling to ambient temperature, the reaction mixture was diluted with CH~2~Cl~2~, filtered through celite, and the filtrate was concentrated under reduced pressure. The crude residue was purified through a silica gel column using hexane and ethyl acetate (85:15) as eluent. The desired product, an orange solid **3a** (91.25 mg) was obtained in 72% yield.

#### 4,5-Diphenylisochromeno\[8,1-*ab*\]phenazine (**3a**) {#sec4.2.1.1}

The compound is prepared according to the general procedure. Orange-colored solid; yield 72% (91.25 mg); mp 228--230 °C; FT-IR (cm^--1^) neat; 2933, 1654, 1437, 1385, 1231, 1159, 1093, 834, 757, 659; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.10 (d, *J* = 8.1 Hz, 1H), 8.28 (d, *J* = 8.3 Hz, 1H), 8.18 (d, *J* = 8.5 Hz, 1H), 7.84--7.80 (m, 1H), 7.78--7.74 (m, 1H), 7.64 (t, *J* = 7.9 Hz, 1H), 7.46--7.36 (m, 5H), 7.34--7.30 (m, 3H), 7.25 (d, *J* = 7.9 Hz, 3H), 7.12 (d, *J* = 7.6 Hz, 1H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.5, 151.6, 149.6, 145.7, 143.5, 140.7, 140.1, 134.8, 133.5, 131.9, 131.6, 131.1, 130.1, 129.7, 129.1, 129.0, 128.8, 128.4, 128.3, 127.9, 127.8, 124.0, 123.4, 122.8, 116.4, 103.1 ppm; HRMS *m*/*z* (ESI): calcd for C~30~H~19~N~2~O \[M + H\]^+^ 423.1497; found 423.1494.

#### 4,5-Di-*p*-tolylisochromeno\[8,1-*ab*\]phenazine (**3b**) {#sec4.2.1.2}

The compound is prepared according to the general procedure. Orange-colored solid; yield 65% (87.85 mg); mp 250--252 °C; FT-IR (cm^--1^) neat; 2975, 1701, 1609, 1538, 1490, 1441, 1365, 1307, 1287, 1234, 1154, 1117, 1059, 977, 910, 864, 811, 748, 683, 652; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.01 (d, *J* = 8.0 Hz, 1H), 8.23 (d, *J* = 7.8 Hz, 1H), 8.14 (d, *J* = 8.0 Hz, 1H), 7.80--7.69 (m, 2H), 7.57 (t, *J* = 7.9 Hz, 1H), 7.22 (dt, *J* = 20.5, 6.1 Hz, 7H), 7.05 (dd, *J* = 14.6, 7.8 Hz, 3H), 2.41 (s, 3H), 2.31 (s, 3H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.6, 149.5, 145.7, 143.5, 140.6, 140.1, 138.7, 137.5, 132.2, 131.9, 131.5, 130.9, 130.8, 130.0, 129.9, 129.6, 129.6, 128.9, 128.5, 128.3, 128.2, 123.7, 123.3, 122.7, 115.8, 102.9, 21.3, 21.3 ppm; HRMS *m*/*z* (ESI): calcd for C~32~H~23~N~2~O \[M + H\]^+^ 451.1810; found 451.1812.

#### 4,5-Bis(4-methoxyphenyl)isochromeno\[8,1-*ab*\]phenazine (**3c**) {#sec4.2.1.3}

The compound is prepared according to the general procedure. Orange-colored solid; yield 57% (82.44 mg); mp 208--210 °C; FT-IR (cm^--1^) neat; 2983, 1694, 1641, 1551, 1481, 1451, 1363, 1308, 1240, 1153, 1066, 1018, 914, 871, 772, 730; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.05 (dd, *J* = 8.1, 1.0 Hz, 1H), 8.26 (dd *J* = 8.4, 1.6 Hz, 1H), 8.16 (dd, *J* = 8.5, 1.5 Hz, 1H), 7.81 (dd, *J* = 8.5, 6.7 Hz, 1H), 7.75 (dd, *J* = 8.2, 6.7 Hz, 1H), 7.63 (t, *J* = 7.9 Hz, 1H), 7.35--7.28 (m, 3H), 7.22 (d, *J* = 8.7 Hz, 2H), 7.12 (dd, *J* = 7.6, 1.0 Hz, 1H), 6.98 (d, *J* = 8.7 Hz, 2H), 6.78 (d, *J* = 9.0 Hz, 2H), 3.87 (s, 3H), 3.80 (s, 3H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 159.7, 159.1, 155.6, 149.4, 145.7, 143.5, 140.6, 140.1, 132.5, 132.2, 131.5, 130.4, 130.0, 129.6, 129.6, 128.3, 128.1, 127.2, 126.0, 123.6, 123.1, 122.6, 114.9, 114.7, 113.3, 102.8, 55.28, 55.2 ppm; HRMS *m*/*z* (ESI): calcd for C~32~H~23~N~2~O~3~ \[M + H\]^+^ 483.1709; found 483.1703.

#### 4,5-Bis(4-fluorophenyl)isochromeno\[8,1-*ab*\]phenazine (**3d**) {#sec4.2.1.4}

The compound is prepared according to the general procedure. Orange-colored solid; yield 64% (88.02 mg); mp 208--210 °C; FT-IR (cm^--1^) neat; 2969, 1688, 1591, 1524, 1446, 1390, 1287, 1237, 1153, 1055, 861, 743, 625; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.07 (dd, *J* = 8.1, 1.0 Hz, 1H), 8.29--8.24 (m, 1H), 8.19--8.13 (m, 1H), 7.81--7.77 (m, 2H), 7.61 (t, *J* = 7.9 Hz, 1H), 7.35--7.30 (m, 2H), 7.29--7.25 (m, 3H), 7.17--7.12 (m, 2H), 7.04 (dd, *J* = 7.6, 1.1 Hz, 1H), 6.98--6.92 (m, 2H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 163.9, 163.6, 161.4, 161.2, 155.1, 148.9, 145.5, 143.5, 140.8, 139.9, 133.4, 133.3, 132.8, 132.8, 131.6, 131.5, 131.0, 130.9, 130.6, 130.5, 130.3, 129.7, 129.7, 129.5, 129.4, 128.5, 128.4, 124.2, 123.1, 122.7, 116.5, 116.3, 115.7, 115.5, 115.4, 115.2, 115.0, 103.3 ppm. HRMS *m*/*z* (ESI): calcd for C~30~H~17~F~2~N~2~O \[M + H\]^+^ 459.1309; found 459.1321.

#### 4,5-Bis(4-chlorophenyl)isochromeno\[8,1-*ab*\]phenazine (**3e**) {#sec4.2.1.5}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 52% (76.65 mg); mp 260--262 °C; FT-IR (cm^--1^) neat; 2967, 2361, 1660, 1592, 1524, 1448, 1385, 1289, 1239, 1155, 1056, 934, 863, 745, 626; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.10 (d, *J* = 8.1 Hz, 1H), 8.27 (d, *J* = 8.2 Hz, 1H), 8.17 (d, *J* = 8.3 Hz, 1H), 7.80 (dt, *J* = 14.9, 7.0 Hz, 2H), 7.63 (t, *J* = 7.9 Hz, 1H), 7.43 (d, *J* = 8.3 Hz, 2H), 7.27 (dd, *J* = 11.1, 6.2 Hz, 7H), 7.05 (d, *J* = 7.6 Hz, 1H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.0, 148.7, 140.8, 139.9, 135.0, 134.1, 133.0, 132.4, 132.4, 131.7, 131.2, 130.4, 130.3, 130.3, 129.7, 129.7, 129.0, 128.5, 128.4, 128.3, 125.7, 124.4, 123.1, 122.7, 115.7, 103.4 ppm. HRMS *m*/*z* (ESI): calcd for C~30~H~17~Cl~2~N~2~O \[M + H\]^+^ 491.0718; found 491.0723.

#### 4,5-Bis(4-bromophenyl)isochromeno\[8,1-*ab*\]phenazine (**3f**) {#sec4.2.1.6}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 50% (87 mg); mp 270--272 °C; FT-IR (cm^--1^) neat; 2969, 1682, 1538, 1512, 1480, 1433, 1375, 1327, 1288, 1231, 1178, 1148, 1068, 988, 915, 682; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.10 (d, *J* = 8.1 Hz, 1H), 8.27 (d, *J* = 8.5 Hz, 1H), 8.17 (d, *J* = 8.3 Hz, 1H), 7.79 (dt, *J* = 14.7, 7.1 Hz, 2H), 7.66--7.57 (m, 3H), 7.40 (d, *J* = 8.5 Hz, 2H), 7.30 (s, 1H), 7.20 (dd, *J* = 13.5, 8.4 Hz, 4H), 7.05 (d, *J* = 7.6 Hz, 1H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.0, 148.7, 140.8, 139.9, 133.5, 132.7, 132.7, 132.1, 131.7, 131.3, 131.1, 130.5, 130.4, 130.3, 129.7, 129.7, 128.6, 128.4, 124.4, 123.4, 123.2, 123.0, 122.7, 122.3, 115.7, 103.5 ppm; HRMS *m*/*z* (ESI): calcd for C~30~H~17~Br~2~N~2~O \[M + H\]^+^ 578.9708; found 578.9705.

#### 4,5-Bis(4-nitrophenyl)isochromeno\[8,1-*ab*\]phenazine (**3g**) {#sec4.2.1.7}

The compound is prepared according to the general procedure. Orange-colored solid; yield 39% (59 mg); mp 188--190 °C; FT-IR (cm^--1^) neat; 2927, 1654, 1551, 1438, 1384, 1241, 1159, 1061, 759; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.19 (d, *J* = 8.1 Hz, 1H), 8.34 (d, *J* = 8.5 Hz, 1H), 8.30 (d, *J* = 8.3 Hz, 1H), 8.20 (d, *J* = 8.4 Hz, 1H), 8.13 (d, *J* = 8.7 Hz, 2H), 7.83 (dt, *J* = 21.8, 7.1 Hz, 3H), 7.69 (d, *J* = 7.8 Hz, 1H), 7.52 (t, *J* = 8.8 Hz, 4H), 7.39 (s, 1H), 7.00 (d, *J* = 7.6 Hz, 1H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 159.3, 154.1, 148.0, 141.2, 139.7, 138.9, 132.1, 131.2, 130.6, 129.9, 129.8, 129.83, 129.7, 129.0, 128.5, 125.4, 124.8, 123.4, 123.2, 122.8, 122.7, 117.5, 117.0, 104.4 ppm; HRMS *m*/*z* (ESI): calcd for C~30~H~17~N~4~O~5~ \[M + H\]^+^ 513.1199; found 513.1196.

#### 4,5-Di(naphthalen-1-yl)isochromeno\[8,1-*ab*\]phenazine (**3h**) {#sec4.2.1.8}

The compound is prepared according to the general procedure. Orange-colored solid; yield 50% (78 mg); mp 188--190 °C; FT-IR (cm^--1^) neat; 2979, 2361, 1726, 1654, 1545, 1374, 1239, 1161, 1097, 1044, 660, 619; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.07 (d, *J* = 8.1 Hz, 1H), 8.28 (d, *J* = 8.4 Hz, 1H), 8.23 (d, *J* = 8.3 Hz, 1H), 8.11 (d, *J* = 8.2 Hz, 1H), 8.01 (d, *J* = 7.9 Hz, 1H), 7.77--7.70 (m, 4H), 7.66--7.60 (m, 2H), 7.50--7.44 (m, 3H), 7.39 (dd, *J* = 16.0, 7.5 Hz, 3H), 7.18 (s, 2H), 7.00 (t, *J* = 7.7 Hz, 1H), 6.87--6.79 (m, 1H), 6.66 (d, *J* = 7.5 Hz, 1H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 151.4, 145.6, 133.6, 133.4, 132.7, 132.6, 132.0, 131.7, 131.7, 131.6, 130.9, 130.2, 129.8, 129.7, 128.5, 128.5, 128.48, 128.46, 128.44, 128.3, 127.9, 127.8, 127.2, 127.1, 126.72, 126.70, 126.4, 126.4, 126.09, 126.00, 125.8, 125.6, 124.7, 124.2, 124.0, 122.4, 120.8, 103.7 ppm; HRMS *m*/*z* (ESI): calcd for C~38~H~23~N~2~O \[M + H\]^+^ 523.1810; found 523.1808.

#### 4-Methyl-5-phenylisochromeno\[8,1-*ab*\]phenazine (**3i**) {#sec4.2.1.9}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 68% (73 mg); mp 234--236 °C; FT-IR (cm^--1^) neat; 2970, 1690, 1592, 1524, 1448, 1288, 1237, 1153, 1056, 826, 743, 678; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.13 (d, *J* = 8.1 Hz, 1H), 8.26 (d, *J* = 8.3 Hz, 1H), 8.15 (d, *J* = 8.4 Hz, 1H), 7.83--7.72 (m, 3H), 7.65 (d, *J* = 7.0 Hz, 2H), 7.51 (d, *J* = 7.6 Hz, 4H), 7.23 (s, 1H), 2.19 (s, 3H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.5, 149.7, 145.6, 143.5, 140.5, 134.0, 131.7, 131.6, 131.5, 130.1, 129.8, 129.6, 129.4, 129.2, 128.39, 128.35, 128.2, 123.8, 123.0, 121.3, 108.4, 102.9, 13.7 ppm; HRMS *m*/*z* (ESI): calcd for C~25~H~16~N~2~O \[M + H\]^+^ 361.1341; found 361.1339.

#### 4,5-Dimethylisochromeno\[8,1-*ab*\]phenazine (**3j**) {#sec4.2.1.10}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 39% (35 mg); mp 140--142 °C; FT-IR (cm^--1^) neat; 2935, 1654, 1386, 1240, 1096, 1044, 842, 749, 660; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.03 (d, *J* = 8.1 Hz, 1H), 8.24 (d, *J* = 8.5 Hz, 1H), 8.13 (d, *J* = 8.5 Hz, 1H), 7.80--7.70 (m, 3H), 7.35 (d, *J* = 7.5 Hz, 1H), 7.13 (s, 1H), 2.25 (s, 3H), 2.06 (s, 3H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 148.4, 143.4, 142.4, 140.5, 140.0, 133.8, 131.5, 130.0, 129.7, 129.6, 128.3, 128.2, 128.0, 122.9, 122.7, 120.2, 106.5, 102.4, 17.1, 12.4 ppm; HRMS *m*/*z* (ESI): calcd for C~20~H~14~N~2~O \[M + H\]^+^ 299.1184; found 299.1186.

#### 4,5-Diethylisochromeno\[8,1-*ab*\]phenazine (**3k**) {#sec4.2.1.11}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 45% (44 mg); mp 150--152 °C; FT-IR (cm^--1^) neat; 2970, 2359, 1688, 1591, 1523, 1447, 1391, 1365, 1287, 1237, 1152, 1055, 942, 861, 816, 773, 747, 683, 660, 625; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.02 (d, *J* = 8.1 Hz, 1H), 8.23 (d, *J* = 8.2 Hz, 1H), 8.13 (d, *J* = 8.0 Hz, 1H), 7.80--7.69 (m, 3H), 7.42 (d, *J* = 7.6 Hz, 1H), 7.13 (s, 1H), 2.56 (q, *J* = 7.5 Hz, 4H), 1.32 (t, *J* = 7.5 Hz, 3H), 1.22 (t, *J* = 7.5 Hz, 3H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.8, 153.3, 149.1, 140.4, 140.0, 131.8, 130.6, 129.9, 129.7, 129.6, 128.3, 127.9, 122.9, 120.8, 120.3, 111.9, 111.4, 102.3, 23.9, 19.4, 13.4, 12.4 ppm; HRMS *m*/*z* (ESI): calcd for C~22~H~19~N~2~O \[M + H\]^+^ 327.1497; found 327.1502.

#### 4,5-Dipropylisochromeno\[8,1-*ab*\]phenazine (**3l**) {#sec4.2.1.12}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 50% (53 mg); mp 178--180 °C; FT-IR (cm^--1^) neat; 2952, 1701, 1652, 1517, 1434, 1390, 1366, 1290, 1238, 1163, 1101, 976, 843, 753, 682; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.02 (d, *J* = 8.1 Hz, 1H), 8.23 (d, *J* = 8.3 Hz, 1H), 8.13 (d, *J* = 8.4 Hz, 1H), 7.79--7.69 (m, 3H), 7.40 (d, *J* = 7.6 Hz, 1H), 7.13 (s, 1H), 2.52 (dd, *J* = 14.6, 6.6 Hz, 4H), 1.78 (dd, *J* = 15.0, 7.5 Hz, 2H), 1.63 (dd, *J* = 15.4, 7.6 Hz, 2H), 1.07 (t, *J* = 7.4 Hz, 6H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.7, 152.5, 145.7, 143.4, 140.4, 140.0, 131.8, 130.9, 129.9, 129.7, 129.6, 128.2, 127.9, 123.1, 122.9, 120.5, 111.1, 102.2, 32.5, 28.4, 21.8, 21.1, 14.2, 13.9 ppm; HRMS *m*/*z* (ESI): calcd for C~24~H~23~N~2~O \[M + H\]^+^ 355.1810; found 355.1811.

#### 4,5-Dibutylisochromeno\[8,1-*ab*\]phenazine (**3m**) {#sec4.2.1.13}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 62% (71 mg); mp 196--198 °C; FT-IR (cm^--1^) neat; 2952, 1701, 1652, 1517, 1434, 1390, 1366, 1290, 1238, 1163, 1101, 976, 843, 753, 682; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.03 (d, *J* = 8.1 Hz, 1H), 8.24 (d, *J* = 8.3 Hz, 1H), 8.13 (d, *J* = 8.5 Hz, 1H), 7.82--7.67 (m, 3H), 7.41 (d, *J* = 7.6 Hz, 1H), 7.13 (s, 1H), 2.53 (dd, *J* = 14.9, 6.9 Hz, 4H), 1.76--1.65 (m, 4H), 1.49 (dd, *J* = 14.9, 7.6 Hz, 4H), 1.00 (t, *J* = 7.3 Hz, 6H); ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.7, 152.6, 145.7, 143.4, 140.4, 140.0, 131.8, 130.9, 129.9, 129.7, 129.6, 128.2, 127.9, 123.1, 122.9, 120.5, 111.1, 102.2, 30.8, 30.3, 29.9, 26.1, 22.9, 22.5, 13.9, 13.9 ppm. HRMS *m*/*z* (ESI): calcd for C~26~H~27~N~2~O \[M + H\]^+^ 383.2123; found 383.213.

#### 11-Methyl-4,5-diphenylisochromeno\[8,1-*ab*\]phenazine (**3n**) {#sec4.2.1.14}

The compound is prepared according to the general procedure. Yellow-colored solid; yield 69% (90 mg); mp: 182--184 °C; FT-IR (cm^--1^) neat; 2969, 1655, 1592, 1524, 1439, 1412, 1388, 1287, 1236, 1154, 1098, 1055, 942, 900, 844, 816, 744; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 9.06 (d, *J* = 8.1 Hz, 1H), 8.17--8.00 (m, 2H), 7.67--7.57 (m, 2H), 7.39 (ddd, *J* = 11.0, 9.6, 4.3 Hz, 5H), 7.32--7.30 (m, 2H), 7.27--7.20 (m, 4H), 7.08 (d, *J* = 7.6 Hz, 1H), 2.65 (s, 3H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.0, 149.5, 145.0, 140.8, 139.9, 138.8, 134.9, 133.6, 132.9, 131.8, 131.6, 131.1, 131.0, 129.6, 129.5, 129.1, 129.0, 128.7, 128.1, 127.8, 127.8, 123.8, 123.7, 123.1, 116.4, 103.2, 21.9 ppm; HRMS *m*/*z* (ESI): calcd for C~31~H~21~N~2~O \[M + H\]^+^ 437.1654; found 437.1648.

#### 10,11-Dibromo-4,5-diphenylisochromeno\[8,1-*ab*\]phenazine (**3o**) {#sec4.2.1.15}

The compound is prepared according to the general procedure. Orange-colored solid; yield 58% (101 mg); mp 200--202 °C; FT-IR (cm^--1^) neat; 2965, 1684, 1548, 1523, 1495, 1448, 1433, 1385, 1338, 1273, 1246, 1193, 1163, 1068, 988; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.97 (d, *J* = 8.1 Hz, 1H), 8.53 (s, 1H), 8.45 (s, 1H), 7.52 (s, 3H), 7.36--7.32 (m, 5H), 7.17--7.09 (m, 4H), 6.70 (s, 1H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 156.4, 147.1, 134.6, 133.3, 132.2, 131.09, 130.10, 129.2, 129.0, 128.9, 128.8, 128.6, 128.6, 128.5, 128.4, 128.2, 128.0, 127.9, 127.6, 124.7, 124.4, 124.2, 124.1, 123.9, 116.8, 102.9 ppm. HRMS *m*/*z* (ESI): calcd for C~30~H~17~Br~2~N~2~O \[M + H\]^+^ 578.9708; found 578.9711.

#### 4,5,10,11-Tetraphenylisochromeno\[8,1-*ab*\]phenazine (**3p**) {#sec4.2.1.16}

The compound is prepared according to the general procedure. Red-colored solid; yield 67% (115 mg); mp 216--218 °C; FT-IR (cm^--1^) neat; 2967, 1648, 1541, 1413, 1385, 1239, 1157, 1069, 993, 865, 816, 754, 660; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.96 (d, *J* = 8.1 Hz, 1H), 8.22 (s, 1H), 8.13 (s, 1H), 7.52 (t, *J* = 7.9 Hz, 1H), 7.37--7.26 (m, 5H), 7.25--7.21 (m, 11H), 7.20--7.12 (m, 5H), 7.00 (d, *J* = 7.6 Hz, 1H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.4, 149.5, 146.0, 143.7, 142.8, 141.9, 140.6, 140.5, 140.4, 140.0, 134.8, 133.5, 131.9, 131.6, 131.1, 130.6, 130.0, 129.7, 129.3, 129.3, 129.2, 129.0, 128.8, 128.0, 127.9, 127.8, 127.1, 127.0, 124.0, 123.3, 122.8, 117.8, 116.5, 103.2 ppm; HRMS *m*/*z* (ESI): calcd for C~42~H~27~N~2~O \[M + H\]^+^ 575.2123; found 575.2118.

#### 4,5,9,12-Tetraphenylisochromeno\[8,1-*ab*\]phenazine (**3q**) {#sec4.2.1.17}

The compound is prepared according to the general procedure. Red-colored solid; yield 70% (121 mg); mp 202--204 °C; FT-IR (cm^--1^) neat; 2969, 2359, 1650, 1544, 1412, 1384, 1329, 1158, 1063, 992, 754, 619, 606; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.74 (d, *J* = 8.0 Hz, 1H), 7.92--7.81 (m, 6H), 7.49 (ddd, *J* = 20.4, 13.6, 7.3 Hz, 8H), 7.34 (d, *J* = 7.3 Hz, 2H), 7.28 (s, 2H), 7.15 (dd, *J* = 17.2, 9.6 Hz, 5H), 7.05 (d, *J* = 8.8 Hz, 1H), 7.00 (d, *J* = 7.7 Hz, 1H); ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.3, 151.8, 151.7, 149.4, 147.0, 144.8, 141.7, 140.1, 139.1, 138.9, 138.8, 138.5, 134.9, 133.6, 131.9, 131.8, 131.2, 131.1, 131.0, 130.8, 130.1, 129.6, 129.1, 128.9, 128.7, 128.3, 128.0, 127.9, 127.8, 127.5, 127.4, 124.3, 123.1, 119.1, 103.7 ppm. HRMS *m*/*z* (ESI): calcd for C~42~H~27~N~2~O \[M + H\]^+^ 575.2123; found 575.2131.

#### 4,4′-(4,5-Diphenylisochromeno\[8,1-*ab*\]phenazine-10,11-diyl)bis(*N*,*N*-diphenylaniline) (**3r**) {#sec4.2.1.18}

The compound is prepared according to the general procedure. Orange-colored solid; yield 56% (158 mg); mp: 202--204 °C; FT-IR (cm^--1^) neat; 2923, 1651, 1592, 1544, 1489, 1439, 1413, 1386, 1235, 1159, 1092, 844, 759, 661, 619; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.98 (d, *J* = 8.1 Hz, 1H), 8.21 (s, 1H), 8.12 (s, 1H), 7.53 (t, *J* = 7.9 Hz, 1H), 7.36--7.27 (m, 5H), 7.24--7.14 (m, 14H), 7.10 (d, *J* = 8.5 Hz, 4H), 7.05 (d, *J* = 8.1 Hz, 8H), 7.01 (d, *J* = 7.6 Hz, 1H), 6.95 (dd, *J* = 12.1, 5.3 Hz, 8H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 155.3, 149.6, 149.0, 147.6, 147.6, 147.0, 146.9, 145.8, 145.8, 143.7, 142.9, 142.9, 141.9, 140.3, 140.2, 140.1, 134.9, 134.7, 134.4, 133.5, 131.9, 131.6, 131.1, 130.8, 129.9, 129.7, 129.3, 129.2, 129.0, 128.8, 128.6, 127.9, 127.8, 124.6, 124.5, 123.9, 123.2, 123.0, 123.0, 122.8, 122.6, 120.8, 116.5, 111.4, 103.3 ppm. HRMS *m*/*z* (ESI): calcd for C~66~H~45~N~4~O \[M + H\]^+^ 909.3593; found 909.3583.

#### 4,5-Diphenylisochromeno\[8,1-*fg*\]quinoxaline-9,10-dicarbonitrile (**3s**) {#sec4.2.1.19}

Yield: The compound is prepared according to the general procedure. Orange-colored solid; yield 67% (85 mg); mp 206--208 °C; FT-IR (cm^--1^) neat; 2925, 2203, 1655, 1543, 1437, 1387, 1235, 1159, 1088, 834, 616; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.78 (d, *J* = 8.1 Hz, 1H), 7.69 (t, *J* = 8.0 Hz, 1H), 7.41--7.33 (m, 3H), 7.28--7.18 (m, 9H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 159.3, 150.2, 145.8, 138.6, 133.7, 132.5, 132.4, 131.8, 131.5, 130.7, 130.3, 129.5, 129.4, 129.0, 128.4, 128.0, 125.6, 124.7, 124.0, 123.9, 117.6, 114.3, 113.8, 103.2 ppm; HRMS *m*/*z* (ESI): calcd for C~28~H~15~N~4~O \[M + H\]^+^ 423.1246; found 423.1242.

#### 4,5-Diphenyl-8*a*,9,10,11,12,12*a*-hexahydroisochromeno\[8,1-*ab*\]phenazine (**3t**) {#sec4.2.1.20}

The compound is prepared according to the general procedure. Green-colored solid; yield 80% (103 mg); mp 184--186 °C; FT-IR (cm^--1^) neat; 2966, 1614, 1551, 1438, 1384, 1360, 1324, 1243, 1161, 1128, 865, 755; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.68 (d, *J* = 8.2 Hz, 1H), 7.40 (t, *J* = 7.9 Hz, 1H), 7.35--7.26 (m, 5H), 7.23--7.19 (m, 2H), 7.14 (dd, *J* = 13.2, 5.7 Hz, 4H), 6.81 (d, *J* = 7.4 Hz, 1H), 3.09 (d, *J* = 15.0 Hz, 4H), 1.97 (t, *J* = 2.9 Hz, 4H), 1.59 (s, 2H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 152.8, 152.4, 148.6, 148.3, 141.3, 134.4, 134.1, 132.8, 130.7, 130.4, 130.1, 128.1, 128.0, 127.9, 127.6, 127.5, 127.5, 126.7, 126.7, 123.7, 121.7, 120.8, 119.5, 115.5, 102.5, 31.8, 31.8, 28.6, 22.0, 21.9 ppm; HRMS *m*/*z* (ESI): calcd for C~30~H~25~N~2~O \[M + H\]^+^ 429.1967; found 429.1961.

#### 10,11-Dibromo-4,5-bis(4-methoxyphenyl)isochromeno\[8,1-*ab*\]phenazine (**3u**) {#sec4.2.1.21}

The compound is prepared according to the general procedure. Red-colored solid; yield 52% (100 mg); mp 184--186 °C; FT-IR (cm^--1^) neat; 2970, 1675, 1544, 1528, 1495, 1448, 1433, 1385, 1338, 1273, 1246, 1193, 1163, 1068, 988; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.54 (s, 1H), 8.45 (s, 1H), 7.64 (dd, *J* = 13.3, 5.4 Hz, 2H), 7.33--7.29 (m, 4H), 7.20 (d, *J* = 1.3 Hz, 2H), 6.99 (s, 1H), 6.76 (s, 1H), 6.72 (d, *J* = 2.1 Hz, 1H), 6.31 (s, 1H), 3.87 (s, 3H), 3.80 (s, 3H); ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 159.8, 159.2, 158.6, 156.5, 139.6, 133.4, 133.3, 132.2, 132.2, 130.4, 130.2, 130.0, 130.0, 126.9, 123.9, 118.7, 115.0, 114.7, 113.8, 113.6, 113.3, 109.8, 104.3, 102.6, 55.3, 55.2 ppm. HRMS *m*/*z* (ESI): calcd for C~32~H~21~Br~2~N~2~O~3~ \[M + H\]^+^ 638.9919; found 638.9916.

#### 4,5-Bis(4-methoxyphenyl)isochromeno\[8,1-*fg*\]quinoxaline-9,10-dicarbonitrile (**3v**) {#sec4.2.1.22}

The compound is prepared according to the general procedure. Red-colored solid; yield 60% (87 mg); mp 214--216 °C; FT-IR (cm^--1^) neat; 2938, 2226, 1688, 1655, 1578, 1431, 1391, 1227, 1160, 1092, 1066, 834, 616; ^1^H NMR (400 MHz, CDCl~3~) δ~H~ 8.83 (d, *J* = 8.2 Hz, 1H), 7.95 (d, *J* = 8.8 Hz, 1H), 7.75 (t, *J* = 7.9 Hz, 1H), 7.31--7.28 (m, 2H), 7.20 (d, *J* = 8.5 Hz, 2H), 6.99 (dd, *J* = 12.4, 8.8 Hz, 3H), 6.78 (d, *J* = 8.8 Hz, 2H), 3.88 (s, 3H), 3.80 (s, 3H) ppm; ^13^C NMR (100 MHz, CDCl~3~) δ~C~ 160.2, 159.5, 150.1, 145.9, 133.1, 132.3, 131.9, 131.5, 130.4, 126.3, 126.0, 125.4, 124.9, 124.4, 123.7, 123.6, 119.4, 117.0, 116.0, 115.0, 114.4, 114.3, 113.5, 103.0, 55.3, 55.3 ppm. HRMS *m*/*z* (ESI): calcd for C~30~H~19~N~4~O~3~ \[M + H\]^+^ 483.1457; found 483.1467.

### Competitive Experiment {#sec4.2.2}

To an oven-dried 25 mL round-bottom flask fitted with a reflux condenser were added benzo\[*a*\]phenazin-5-ol **1a** (73.88 mg, 0.3 mmol, 1.0 equiv), diphenyl acetylene **2a** (53.43 mg, 0.3 mmol, 1.0 equiv), **2l** (36.06 mg, 0.3 mmol, 1.0 equiv), \[RuCl2(*p*-cymene)\]~2~ (9.18 mg, 0.015 mmol, 0.05 equiv), AgSbF~6~ (20.62 mg, 0.06 mmol, 0.2 equiv), Cu(OAc)~2~·H~2~O (59.89 mg, 0.3 mmol, 1.0 equiv) in 3.0 mL of 1,2-DCE. The reaction mixture was refluxed for 12 h. After cooling to the ambient temperature, the reaction mixture was diluted with CH~2~Cl~2~ and filtered through celite and the filtrate was concentrated under reduced pressure. The crude residue was purified through a silica gel column using hexane and ethyl acetate (85:15) as eluent. The desired products **3a** and **3l** were obtained as orange solids. ^1^H NMR analysis confirmed that the annulated product originating from the electron-deficient alkyne, **3a**, was obtained in higher proportion, 1.7:1.0, when compared to that obtained from **3l**.

### Regioselectivity of the Reaction {#sec4.2.3}

To an oven-dried 25 mL round-bottom flask fitted with a reflux condenser were added benzo\[*a*\]phenazin-5-ol **1a** (73.88 mg, 0.3 mmol, 1.0 equiv), 1-phenyl-1-propyne **2i** (34.84 mg, 0.3 mmol, 1.0 equiv), \[RuCl~2~(*p*-cymene)\]~2~ (5.0 mol %), Cu(OAc)~2~·H~2~O (1 equiv), and AgSbF~6~ (20 mol %) in 1,2-DCE. The reaction mixture was refluxed for 12 h. After cooling to the ambient temperature, the reaction mixture was diluted with CH~2~Cl~2~ and filtered through celite and the filtrate was concentrated under reduced pressure. The crude residue was purified through a silica gel column using hexane and ethyl acetate (85:15) as eluents. The desired product, orange solid **3i**, 73.52 mg, was obtained in 68% yield. The regioselectivity of the annulated product was confirmed by the nuclear Overhauser effect experiment.

### Preliminary Mechanism Study {#sec4.2.4}

\(1\) To an oven-dried 25 mL round-bottom flask fitted with a reflux condenser were added benzo\[*a*\]phenazin-5-ol **1** (0.3 mmol) and CD~3~OD (10 equiv) in 1,2-DCE. This mixture was refluxed for 12 h. After cooling to the ambient temperature, the solvent was evaporated under reduced pressure and the residue was purified by flash column chromatography on silica gel to give the mixture **1a**/**1aa**. The mixture was analyzed using ^1^H NMR spectrometer. The deuterium incorporation was estimated to be 69%. (2) To an oven-dried 25 mL round-bottom flask fitted with a reflux condenser were added benzo\[*a*\]phenazin-5-ol **1** (0.3 mmol), acetylene **2** (0.3 mmol), \[RuCl~2~(*p*-cymene)\]~2~ (5.0 mol %), Cu(OAc)~2~·H~2~O (1 equiv), AgSbF~6~ (20 mol %), and CD~3~OD (10 equiv) in 1,2-DCE. This mixture was refluxed for 12 h. After cooling to the ambient temperature, the solvent was evaporated under reduced pressure, and the residue was purified by flash column chromatography on silica gel to give the mixture **1a**/**1ab**. The mixture was analyzed using ^1^H NMR spectrometer. The deuterium incorporation was estimated to be 66 and 75%.

### Gram Scale Synthesize of 4,5-Diphenylisochromeno\[8,1-*ab*\]phenazine {#sec4.2.5}

To an oven-dried 100 mL round-bottom flask fitted with a reflux condenser were added benzo\[*a*\]phenazin-5-ol **1a** (1.03 g, 4.2 mmol, 1.0 equiv), diphenyl acetylene **2a** (0.722 g, 4.2 mmol, 1.0 equiv), \[RuCl~2~(*p*-cymene)\]~2~ (128 mg, 5.0 mol %), Cu(OAc)~2~·H~2~O (0.8350 g, 1.0 equiv), and AgSbF~6~ (0.287 g, 0.2 equiv) in 50 mL of 1,2-DCE. The reaction mixture was refluxed for 12 h. After cooling to the ambient temperature, the reaction mixture was diluted with CH~2~Cl~2~ and filtered through celite and the filtrate was concentrated under reduced pressure. The crude residue was purified through a silica gel column using hexane and ethyl acetate as eluent (85:15) to afford **3a** in 66% (1.17g) yield.

Computational Calculations {#sec4.3}
--------------------------

DFT calculation of compound **3p** was carried out using the Gaussian 09 program package. Ground state geometries of the boron dyes were optimized using DFT-B3LYP-6-311G basis set. To get information about absorption properties, time-dependent density functional theory calculations are carried out using the optimized geometries.

Live Cancer Cell-Imaging Experiment {#sec4.4}
-----------------------------------

Fluorescence compound **3p** was examined for intracellular imaging in A549, HepG2, and U937 cells. A549 and HepG2 cells were grown in Dulbecco's modified Eagle's medium (DMEM), and U937 cells were grown in RMPI media, with 10% fetal bovine serum, 1% penicillin/streptomycin at 37 °C under a 5% CO~2~ atmosphere for 24 h. The cells were incubated at 37 °C with 10 μM of compound **3p** for 30 min. After thorough washing with phosphate-buffered saline (PBS), the cells were stained with nucleus staining dye DAPI (2 μM) for another 20 min. Thereafter, the staining solution was replaced with fresh PBS to remove the remaining dye. Finally, the blue and red fluorescence images of A549, HepG2, and U937 cells were captured using a confocal laser scanning microscope (LSM710; ZEISS). The excitation wavelength for blue: 405 nm; emission collection: 410--460 nm; excitation wavelength for red: 561 nm; emission collection: 570--680 nm.

Cell Viability Assay {#sec4.5}
--------------------

Cytotoxic properties of the synthesized compound **3p** were studied against A549, HepG2, and U937 cells. A549 and HepG2 cells were maintained in a complete tissue culture medium DMEM, and U937 cells were maintained in Roswell Park Memorial Institute medium, with 10% fetal bovine serum and 2 mM [l]{.smallcaps}-glutamine, along with antibiotics (about 100 IU mL^--1^ of penicillin, 100 μg mL^--1^ of streptomycin), with the pH adjusted to 7.2. A medium of 50 μL containing 5000 cells per well and different concentrations of compounds **3p** was seeded in 96-well plates. The cells were cultivated at 37 °C, with 5% CO~2~ and 95% air, in 100% relative humidity. AQueous One Solution reagent of 20 μL was added to each well of CellTiter 96 according to the manufacturer's guidelines and incubated at 37 °C for 1--4 h under a humidified, 5% CO~2~ atmosphere. The cytotoxicity against cells was determined by measuring the absorbance of the converted dye at 490 nm in an enzyme-linked immunosorbent (immunoadsorbent) assay reader. Cytotoxicity of each sample was expressed as an IC~50~ value.

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b00335](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b00335).Experimental procedures; crystal structural data for compound **3a** (CCDC reference number 1503529); NMR spectra; UV--vis spectra; fluorescence spectra; computational methods; live cell-imaging experiment; cell viability assay ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00335/suppl_file/ao7b00335_si_001.pdf))Crystallographic data for compounds **3a**--**v** ([CIF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00335/suppl_file/ao7b00335_si_002.cif))
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